NeuroPace (NPCE) Q3 2026 Earnings Call Transcript
NeuroPace reported Q3 2026 revenue of $23.1M, missing expectations. CEO Joel Becker attributed the shortfall to transient issues, including account-specific operational challenges and sales team transitions. The company revised full-year revenue guidance to $91M-$92M and expects 15% core RNS revenue growth in 2027, accelerating to 20% by year-end. CMS increased the hospital outpatient payment rate for RNS replacement procedures by 11% for 2027.
How this was made

The 30-second read
Why it matters
The revised guidance and earnings miss are likely to trigger a sell‑off, but longer‑term catalysts could mitigate the downside.
Market read
First public disclosure of revised 2026 guidance for a micro‑cap medical‑device firm; immediate price impact expected.
What to watch
Potential upside from CMS reimbursement increase for RNS replacements and upcoming IGE indication approval.
Background
NeuroPace's Q3 earnings call highlighted operational issues, sales leadership changes, and exit from SEEG distribution, culminating in a revised revenue outlook.
Ticker impact
NeuroPace reported Q3 2026 revenue of $23.1M, missed expectations and revised full-year 2026 revenue guidance to $91M-$92M.
likely downside as investors price in weaker guidance and execution challenges
The transcript provides the first public disclosure of revised 2026 guidance, a material change that typically moves the stock lower.
Market effects
May weigh on other neurotechnology and medical device stocks as investors reassess growth forecasts.
Limited to U.S. small-cap biotech/medical device segment.
Low; impact confined to niche sector.
Counterpoint
If the company can successfully expand its account base and launch new indications, the guidance cut may be temporary.
Key entities
- CompanyNeuroPace
Medical device maker of the RNS system for epilepsy.
- RegulatorCMS
U.S. Centers for Medicare & Medicaid Services, released OPPS rule increasing replacement procedure payment.

